Scienture Holdings, Inc. - 8-K Filing
Scienture Holdings reports Q3 2026 revenue of $1.25 million, up 265% sequentially following REZENOPY™ commercial launch. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $MEDS